Translating Institutional Science into Commercial Reality

November 18, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 11/18/2020 12:00:43 PM 11/18/2020 1:00:43 PM Translating Institutional Science into Commercial Reality In this forum, an expert roundtable will discuss the challenges and triumphs of translating science generated within large area educational/research institutions into commercial and therapeutic reality. Achieving this goal requires meeting the unique challenges involved in satisfying the sometimes divergent institutional and commercial interests of the key players involved. The panel will attempt to shed light on these issues that persist in our biotechnology ecosystem.

Those looking to better understand the intricacies and legal processes associated with working with tech transfer offices, academic/industry collaborations, or engaging with large pharma should attend.

MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning. Webinar, click "live-stream" button to view

General Counsel, Atalanta Therapeutics

Bart Newland is General Counsel of Atalanta Therapeutics, a Series-A funded startup focusing on novel therapies for neurological disorders. Bart previously has served as Senior Vice President and Chief IP Counsel of Biogen, Vice President for Intellectual Property of Genzyme, and as a shareholder of Rothwell, Figg, Ernst & Manbeck. Bart earned his J.D. at William and Mary Law School, where he currently serves on the Board of Directors of the Alumni Association. He earned his B.S. degree with honors in Microbiology from the University of Massachusetts.